Solomayer et al. investigated 137 primary breast cancer patients with regard to the HER2 status of DTCs; 38% of patients with HER2 negative breast cancer presented with HER2 positive DTCs [39]. The gene discussed is ERBB2; the disease is breast carcinoma.